Cargando…

Lipoprotein(a) and Subclinical Vascular and Valvular Calcification on Cardiac Computed Tomography: The Atherosclerosis Risk in Communities Study

BACKGROUND: Lipoprotein(a) (Lp(a)) is a potent causal risk factor for cardiovascular events and mortality. However, its relationship with subclinical atherosclerosis, as defined by arterial calcification, remains unclear. This study uses the ARIC (Atherosclerosis Risk in Communities Study) to evalua...

Descripción completa

Detalles Bibliográficos
Autores principales: Obisesan, Olufunmilayo H., Kou, Minghao, Wang, Frances M., Boakye, Ellen, Honda, Yasuyuki, Uddin, S. M. Iftekhar, Dzaye, Omar, Osei, Albert D., Orimoloye, Olusola A., Howard‐Claudio, Candace M., Coresh, Josef, Blumenthal, Roger S., Hoogeveen, Ron C., Budoff, Matthew J., Matsushita, Kunihiro, Ballantyne, Christie M., Blaha, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238743/
https://www.ncbi.nlm.nih.gov/pubmed/35656990
http://dx.doi.org/10.1161/JAHA.121.024870
_version_ 1784737131960205312
author Obisesan, Olufunmilayo H.
Kou, Minghao
Wang, Frances M.
Boakye, Ellen
Honda, Yasuyuki
Uddin, S. M. Iftekhar
Dzaye, Omar
Osei, Albert D.
Orimoloye, Olusola A.
Howard‐Claudio, Candace M.
Coresh, Josef
Blumenthal, Roger S.
Hoogeveen, Ron C.
Budoff, Matthew J.
Matsushita, Kunihiro
Ballantyne, Christie M.
Blaha, Michael J.
author_facet Obisesan, Olufunmilayo H.
Kou, Minghao
Wang, Frances M.
Boakye, Ellen
Honda, Yasuyuki
Uddin, S. M. Iftekhar
Dzaye, Omar
Osei, Albert D.
Orimoloye, Olusola A.
Howard‐Claudio, Candace M.
Coresh, Josef
Blumenthal, Roger S.
Hoogeveen, Ron C.
Budoff, Matthew J.
Matsushita, Kunihiro
Ballantyne, Christie M.
Blaha, Michael J.
author_sort Obisesan, Olufunmilayo H.
collection PubMed
description BACKGROUND: Lipoprotein(a) (Lp(a)) is a potent causal risk factor for cardiovascular events and mortality. However, its relationship with subclinical atherosclerosis, as defined by arterial calcification, remains unclear. This study uses the ARIC (Atherosclerosis Risk in Communities Study) to evaluate the relationship between Lp(a) in middle age and measures of vascular and valvular calcification in older age. METHODS AND RESULTS: Lp(a) was measured at ARIC visit 4 (1996–1998), and coronary artery calcium (CAC), together with extracoronary calcification (including aortic valve calcium, aortic valve ring calcium, mitral valve calcification, and thoracic aortic calcification), was measured at visit 7 (2018–2019). Lp(a) was defined as elevated if >50 mg/dL and CAC/extracoronary calcification were defined as elevated if >100. Logistic and linear regression models were used to evaluate the association between Lp(a) and CAC/extracoronary calcification, with further stratification by race. The mean age of participants at visit 4 was 59.2 (SD 4.3) years, with 62.2% women. In multivariable adjusted analyses, elevated Lp(a) was associated with higher odds of elevated aortic valve calcium (adjusted odds ratio [aOR], 1.82; 95% CI, 1.34–2.47), CAC (aOR, 1.40; 95% CI, 1.08–1.81), aortic valve ring calcium (aOR, 1.36; 95% CI, 1.07–1.73), mitral valve calcification (aOR, 1.37; 95% CI, 1.06–1.78), and thoracic aortic calcification (aOR, 1.36; 95% CI, 1.05–1.77). Similar results were obtained when Lp(a) and CAC/extracoronary calcification were examined on continuous logarithmic scales. There was no significant difference in the association between Lp(a) and each measure of calcification by race or sex. CONCLUSIONS: Elevated Lp(a) at middle age is significantly associated with vascular and valvular calcification in older age, represented by elevated CAC, aortic valve calcium, aortic valve ring calcium, mitral valve calcification, thoracic aortic calcification. Our findings encourage assessing Lp(a) levels in individuals with increased cardiovascular disease risk, with subsequent comprehensive vascular and valvular assessment where elevated.
format Online
Article
Text
id pubmed-9238743
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92387432022-06-30 Lipoprotein(a) and Subclinical Vascular and Valvular Calcification on Cardiac Computed Tomography: The Atherosclerosis Risk in Communities Study Obisesan, Olufunmilayo H. Kou, Minghao Wang, Frances M. Boakye, Ellen Honda, Yasuyuki Uddin, S. M. Iftekhar Dzaye, Omar Osei, Albert D. Orimoloye, Olusola A. Howard‐Claudio, Candace M. Coresh, Josef Blumenthal, Roger S. Hoogeveen, Ron C. Budoff, Matthew J. Matsushita, Kunihiro Ballantyne, Christie M. Blaha, Michael J. J Am Heart Assoc Original Research BACKGROUND: Lipoprotein(a) (Lp(a)) is a potent causal risk factor for cardiovascular events and mortality. However, its relationship with subclinical atherosclerosis, as defined by arterial calcification, remains unclear. This study uses the ARIC (Atherosclerosis Risk in Communities Study) to evaluate the relationship between Lp(a) in middle age and measures of vascular and valvular calcification in older age. METHODS AND RESULTS: Lp(a) was measured at ARIC visit 4 (1996–1998), and coronary artery calcium (CAC), together with extracoronary calcification (including aortic valve calcium, aortic valve ring calcium, mitral valve calcification, and thoracic aortic calcification), was measured at visit 7 (2018–2019). Lp(a) was defined as elevated if >50 mg/dL and CAC/extracoronary calcification were defined as elevated if >100. Logistic and linear regression models were used to evaluate the association between Lp(a) and CAC/extracoronary calcification, with further stratification by race. The mean age of participants at visit 4 was 59.2 (SD 4.3) years, with 62.2% women. In multivariable adjusted analyses, elevated Lp(a) was associated with higher odds of elevated aortic valve calcium (adjusted odds ratio [aOR], 1.82; 95% CI, 1.34–2.47), CAC (aOR, 1.40; 95% CI, 1.08–1.81), aortic valve ring calcium (aOR, 1.36; 95% CI, 1.07–1.73), mitral valve calcification (aOR, 1.37; 95% CI, 1.06–1.78), and thoracic aortic calcification (aOR, 1.36; 95% CI, 1.05–1.77). Similar results were obtained when Lp(a) and CAC/extracoronary calcification were examined on continuous logarithmic scales. There was no significant difference in the association between Lp(a) and each measure of calcification by race or sex. CONCLUSIONS: Elevated Lp(a) at middle age is significantly associated with vascular and valvular calcification in older age, represented by elevated CAC, aortic valve calcium, aortic valve ring calcium, mitral valve calcification, thoracic aortic calcification. Our findings encourage assessing Lp(a) levels in individuals with increased cardiovascular disease risk, with subsequent comprehensive vascular and valvular assessment where elevated. John Wiley and Sons Inc. 2022-06-03 /pmc/articles/PMC9238743/ /pubmed/35656990 http://dx.doi.org/10.1161/JAHA.121.024870 Text en © 2022 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Obisesan, Olufunmilayo H.
Kou, Minghao
Wang, Frances M.
Boakye, Ellen
Honda, Yasuyuki
Uddin, S. M. Iftekhar
Dzaye, Omar
Osei, Albert D.
Orimoloye, Olusola A.
Howard‐Claudio, Candace M.
Coresh, Josef
Blumenthal, Roger S.
Hoogeveen, Ron C.
Budoff, Matthew J.
Matsushita, Kunihiro
Ballantyne, Christie M.
Blaha, Michael J.
Lipoprotein(a) and Subclinical Vascular and Valvular Calcification on Cardiac Computed Tomography: The Atherosclerosis Risk in Communities Study
title Lipoprotein(a) and Subclinical Vascular and Valvular Calcification on Cardiac Computed Tomography: The Atherosclerosis Risk in Communities Study
title_full Lipoprotein(a) and Subclinical Vascular and Valvular Calcification on Cardiac Computed Tomography: The Atherosclerosis Risk in Communities Study
title_fullStr Lipoprotein(a) and Subclinical Vascular and Valvular Calcification on Cardiac Computed Tomography: The Atherosclerosis Risk in Communities Study
title_full_unstemmed Lipoprotein(a) and Subclinical Vascular and Valvular Calcification on Cardiac Computed Tomography: The Atherosclerosis Risk in Communities Study
title_short Lipoprotein(a) and Subclinical Vascular and Valvular Calcification on Cardiac Computed Tomography: The Atherosclerosis Risk in Communities Study
title_sort lipoprotein(a) and subclinical vascular and valvular calcification on cardiac computed tomography: the atherosclerosis risk in communities study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238743/
https://www.ncbi.nlm.nih.gov/pubmed/35656990
http://dx.doi.org/10.1161/JAHA.121.024870
work_keys_str_mv AT obisesanolufunmilayoh lipoproteinaandsubclinicalvascularandvalvularcalcificationoncardiaccomputedtomographytheatherosclerosisriskincommunitiesstudy
AT kouminghao lipoproteinaandsubclinicalvascularandvalvularcalcificationoncardiaccomputedtomographytheatherosclerosisriskincommunitiesstudy
AT wangfrancesm lipoproteinaandsubclinicalvascularandvalvularcalcificationoncardiaccomputedtomographytheatherosclerosisriskincommunitiesstudy
AT boakyeellen lipoproteinaandsubclinicalvascularandvalvularcalcificationoncardiaccomputedtomographytheatherosclerosisriskincommunitiesstudy
AT hondayasuyuki lipoproteinaandsubclinicalvascularandvalvularcalcificationoncardiaccomputedtomographytheatherosclerosisriskincommunitiesstudy
AT uddinsmiftekhar lipoproteinaandsubclinicalvascularandvalvularcalcificationoncardiaccomputedtomographytheatherosclerosisriskincommunitiesstudy
AT dzayeomar lipoproteinaandsubclinicalvascularandvalvularcalcificationoncardiaccomputedtomographytheatherosclerosisriskincommunitiesstudy
AT oseialbertd lipoproteinaandsubclinicalvascularandvalvularcalcificationoncardiaccomputedtomographytheatherosclerosisriskincommunitiesstudy
AT orimoloyeolusolaa lipoproteinaandsubclinicalvascularandvalvularcalcificationoncardiaccomputedtomographytheatherosclerosisriskincommunitiesstudy
AT howardclaudiocandacem lipoproteinaandsubclinicalvascularandvalvularcalcificationoncardiaccomputedtomographytheatherosclerosisriskincommunitiesstudy
AT coreshjosef lipoproteinaandsubclinicalvascularandvalvularcalcificationoncardiaccomputedtomographytheatherosclerosisriskincommunitiesstudy
AT blumenthalrogers lipoproteinaandsubclinicalvascularandvalvularcalcificationoncardiaccomputedtomographytheatherosclerosisriskincommunitiesstudy
AT hoogeveenronc lipoproteinaandsubclinicalvascularandvalvularcalcificationoncardiaccomputedtomographytheatherosclerosisriskincommunitiesstudy
AT budoffmatthewj lipoproteinaandsubclinicalvascularandvalvularcalcificationoncardiaccomputedtomographytheatherosclerosisriskincommunitiesstudy
AT matsushitakunihiro lipoproteinaandsubclinicalvascularandvalvularcalcificationoncardiaccomputedtomographytheatherosclerosisriskincommunitiesstudy
AT ballantynechristiem lipoproteinaandsubclinicalvascularandvalvularcalcificationoncardiaccomputedtomographytheatherosclerosisriskincommunitiesstudy
AT blahamichaelj lipoproteinaandsubclinicalvascularandvalvularcalcificationoncardiaccomputedtomographytheatherosclerosisriskincommunitiesstudy